Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Maintain Funding for COVID Pill beyond April: Academic Societies to Govt
Three Japanese academic associations on February 8 submitted a request to Health Minister Keizo Takemi, urging the government to continue public funding for oral COVID-19 medicines beyond April to help keep down patients’ out-of-pocket payments. In Japan, three oral therapies…
To read the full story
Related Article
- Japan to End Public Aid for COVID Drugs at March-End
February 21, 2024
- Academic Societies to Urge Govt to Continue Funding for COVID Pills beyond April
February 5, 2024
- Transitional Pneumovax Program for Age 70 and Up Set to End in March
December 4, 2023
- Keep Public Funding for COVID Drugs to Get through This Winter: Academic Societies
May 25, 2023
- Japan to Offer COVID Drugs for Free until September-End
March 13, 2023
REGULATORY
- LDP Wins Landslide Victory in Lower House Election; Ex-Lawmakers Return as Centrists Routed
February 9, 2026
- MHLW Panel Deems 10 “Drug Loss” Products as High-Need, to Seek Development
February 9, 2026
- MHLW to Allow OTC Drugs to Match Prescription Doses under Specific Conditions
February 5, 2026
- Japan Launches Biotechnology Working Group, Roadmap Draft Due in April
February 4, 2026
- Japan Panel Backs Nonprescription Switch of Second Emergency Contraceptive
February 4, 2026
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…